IVD Labeling Under 21 CFR 809: A Practical Guide

21 CFR Part 809 is the labeling regulation for in vitro diagnostic products — the reagents, instruments, and systems used to examine specimens taken from the human body. It sits alongside, not inside, the QMSR: Part 809 tells you what your label and package insert must say; the QMSR (through § 809.20) tells you what quality system has to produce them. A finished IVD kit, a general-purpose reagent, an analyte specific reagent, and a research-stage product each carry a different labeling obligation under this part, and getting the category wrong, not just the wording, is one of the common ways small teams end up misbranded.

This guide walks each labeling obligation in Part 809 element by element, what evidence a reviewer expects to see behind it, and where it joins the ISO 13485 and QMSR clauses your quality system already runs on. It closes with the findings that recur most often and a set of frequently asked questions.

Section references in this guide are to 21 CFR Part 809 as currently in force. Because Part 809 is a live-source regulation, always confirm the current text at eCFR.gov before finalizing labeling — a citation here is a starting point for your own review, not a substitute for it.

Does Part 809 apply to your product?

§ 809.3 defines an in vitro diagnostic product as a reagent, instrument, or system intended for use in the diagnosis of disease or other conditions — including a determination of the state of health — to cure, mitigate, treat, or prevent disease or its sequelae, and intended for use in the collection, preparation, and examination of specimens taken from the human body. These products are devices as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act, and may also be biological products subject to section 351 of the Public Health Service Act. § 809.3(b) further defines a product class as all products intended for a particular determination or a related group of determinations, sharing common bioresearch, chemical, or physical characteristics.

Part 809 does not treat every IVD product the same way. Which labeling content set applies turns on what the product is and where it sits in development — not on company size or how formal your labeling process already is.

The IVD label: what § 809.10(a) requires

§ 809.10(a) sets the content the label itself — not the accompanying insert — must state, except where not applicable or as otherwise provided in a product-class standard. The proprietary and established (common or usual) name, if any; the intended use or uses of the product; a statement of warnings or precautions and the statement “For In Vitro Diagnostic Use”— a prescription IVD additionally bears the “Rx only” symbol statement or the restricted-device caution statement; for a reagent, appropriate storage instructions and a means, such as an expiration date based on those storage instructions, by which the user can be assured the product meets identity, strength, quality, and purity standards at time of use; net quantity of contents; the name and place of business of the manufacturer, packer, or distributor; and a lot or control number from which the complete manufacturing history can be determined.

What if the immediate container is too small?

§ 809.10(a) allows for this directly: where an immediate container is too small to bear all required information and is packaged within an outer container, specified items may appear in the outer-container labeling only. That allowance is a packaging accommodation, not a content reduction — every applicable element still has to appear somewhere in the labeling a user sees before use.

Lot traceability is a label requirement, not just a records one

The lot or control number on the label has to trace to the complete manufacturing history — including, where applicable, individual units and functional subassemblies. A numbering scheme that exists in your device history records but doesn’t appear on the label itself doesn’t satisfy § 809.10(a): the traceability has to be reachable from what ships.

The package insert: what § 809.10(b) requires

Labeling that accompanies each IVD product, typically a package insert, has to state the required content in one place, in the format and order § 809.10(b) specifies, except where not applicable or as specified in a product-class standard. The set covers the product name; intended use and type of procedure; a summary and explanation of the test; the principles of the procedure; reagent and instrument information; specimen collection and preparation; a step-by-step procedure; how results are obtained; the procedure’s limitations, including known interfering substances; expected values, identifying the population on which the range was established; specific performance characteristics such as accuracy, precision, specificity, and sensitivity; a bibliography; the manufacturer, packer, or distributor identity; and the date of the last labeling revision, identified as such.

Two reduced-content allowances

§ 809.10(b) doesn’t apply the full content set uniformly. Labeling for a multiple-purpose instrument used for diagnostic purposes, not committed to specific diagnostic procedures or systems, may bear only the subset of items § 809.10(b) lists for that case. Labeling for a reagent intended as a replacement in a diagnostic system may be limited to the information necessary to identify the reagent adequately and describe its proper use. Applying the full fifteen-item insert template to a replacement reagent is over-labeling, not extra caution — confirm which allowance applies before drafting.

Expected values and performance characteristics are the elements most often thin

A package insert can look complete, every section header present, while the expected-values section omits the population the range was established on, or the performance-characteristics section states a single sensitivity figure with no supporting study description. § 809.10(b) requires both — the figures and the basis for them: identify the population, and state the specific performance characteristics, not just a summary claim of accuracy.

Version and date every labeling revision. § 809.10(b) requires the date of the last revision to appear on the insert itself, identified as such — a document-control system that tracks revisions internally but doesn’t carry the date onto the shipped labeling doesn’t satisfy this element.

Research Use Only and Investigational Use Only labeling

§ 809.10(c) exempts a shipment or delivery of an IVD product from the § 809.10(a) and (b) labeling requirements when distributed for an investigation, provided the applicable conditions — including, where part 812 applies, compliance with part 812 — are met. In exchange, the labeling has to carry one of two prominently placed statements, chosen by development stage rather than by preference.

Two statements, gated by development stage

A product in the laboratory research phase of development, not represented as an effective IVD, bears the statement “For Research Use Only. Not for use in diagnostic procedures.” A product shipped or delivered for product testing prior to full commercial marketing bears the statement “For Investigational Use Only. The performance characteristics of this product have not been established.” These aren’t interchangeable disclaimers — they describe different stages, and using the wrong one misrepresents where the product actually sits.

Define, in a labeling or design-control procedure, which development stage maps to which statement, and require the prominent statement on all labeling before shipment while that stage applies. Removing the statement is itself a controlled event: it should happen only on documented readiness for full § 809.10(a)/(b) labeling, not on a release-date deadline that outruns validation.

General-purpose laboratory reagents and equipment

§ 809.10(d) recognizes that some laboratory reagents and equipment have uses generally known by persons trained in their use — hydrochloric acid is the example the regulation itself gives. Labeling for a product that genuinely meets that description need not bear the § 809.10(a) and (b) directions for use, provided it meets the § 809.10(d) content instead: the proprietary and established name; a declaration of the reagent ingredient’s quantity, proportion, or concentration, and for biological materials, source and activity; a statement of purity and quality, including a quantitative declaration of any impurities present; a statement of warnings or precautions and the statement “For Laboratory Use”; appropriate storage instructions; net quantity of contents; the manufacturer, packer, or distributor identity; and a lot or control number. Labeling for general-purpose equipment separately needs a statement adequately describing the product, its composition, and physical characteristics where necessary for proper use.

The classification decision comes first, and it’s a judgment about the product itself, not a labeling shortcut: a reagent sold for general laboratory work qualifies; the same chemical sold as a named component of a specific diagnostic procedure does not, and reverts to full § 809.10(a)/(b) content. Document the classification and its basis, not just the resulting label.

Analyte specific reagents: labeling and distribution

Analyte specific reagents, for which the regulation’s example is monoclonal antibodies, carry their own § 809.10(e) label content: the proprietary and established name; a declaration of the reagent ingredient’s quantity, proportion, or concentration, and for biological materials, source and activity; a statement of purity and quality including a quantitative declaration of impurities and method of analysis or characterization; a statement of warnings or precautions; the date of manufacture and storage instructions; net quantity of contents; the manufacturer, packer, or distributor identity; and a lot or control number. Where an immediate container can’t accommodate the content and is packaged within an outer container, the same outer-container allowance from § 809.10(a) applies.

The class-specific disclosure statement

The label also has to carry a statement disclosing that analytical and performance characteristics aren’t established by the manufacturer — worded by ASR class. A class I exempt ASR bears “Analyte Specific Reagent. Analytical and performance characteristics are not established.” A class II or III ASR bears the corresponding statement that characteristics aren’t established except as a component of the named approved or cleared test. Applying the wrong class’s statement misrepresents the reagent’s validation status — confirm the ASR’s classification before the label ships, not after.

Distribution: a restricted device, sold only to eligible customers

ASRs are restricted devices under section 520(e) of the FD&C Act, and § 809.30 limits who can buy one: IVD manufacturers; CLIA-regulated clinical laboratories qualified to perform high-complexity testing under 42 CFR part 493 (or laboratories regulated under VHA Directive 1106); and organizations using the reagents for purposes other than providing diagnostic information to patients and practitioners — forensic, academic, research, and other nonclinical laboratories. § 809.30(g) carves that eligibility test back out for sales to manufacturers or to those nonclinical-purpose organizations: the § 809.30(c) through (f) labeling, advertising, and laboratory-disclosure requirements don’t apply to that carve-out.

Advertising and promotional materials for ASRs must include the reagent’s identity and purity, including source and method of acquisition, and the analyte’s identity, plus the applicable class statement, and must never make a claim about analytical or clinical performance. A laboratory that develops an in-house test using an ASR has to append a disclosure statement to the test report — that the test was developed and its performance characteristics determined by the laboratory, and hasn’t been cleared or approved by FDA — except when the results come from the test that was cleared or approved in conjunction with review of the class II or III ASR. Ordering an in-house test built on an ASR is itself limited under section 520(e) to physicians and other persons authorized by applicable state law.

OTC drugs-of-abuse test collection systems

Over-the-counter test sample collection systems for drugs-of-abuse testing are restricted devices under section 520(e), and § 809.10(f) and § 809.40 together govern them — the former sets the labeling content, the latter the testing and communication restrictions around it.

Labeling written for a lay purchaser, not a laboratorian

§ 809.10(f) requires labeling in language appropriate for the intended lay users: adequate instructions for specimen collection, handling, preparation, and mailing; an identification system that prevents specimen mix-ups and maintains user anonymity; the intended use, including which drugs are identified, a quantitative description of the performance characteristics for those drugs, sensitivity and specificity, in terms understandable to lay users, and the detection period; a statement that confirmatory testing will be conducted on all initially positive samples; warnings or precautions established under 16 CFR part 1500 and any other warnings appropriate to the product’s hazard (§ 809.10(f)(5)); and adequate instructions on obtaining and interpreting results, including the probability of false positive and false negative results and how to contact a trained health professional.

The testing and communication path § 809.40 requires

§ 809.40 requires the actual sample testing to run through a laboratory using screening tests FDA has approved, cleared, or otherwise recognized as accurate and reliable, with the laboratory recognized as having adequate capability to reliably perform the necessary screening and confirmatory tests — including integrity checks for possible specimen adulteration. The collection system’s labeling must also provide an adequate system to communicate the proper interpretation of results from the laboratory back to the lay purchaser. Routing specimens to a laboratory without that recognized capability, or shipping a system with no result-interpretation path, is a § 809.40 gap even if the § 809.10(f) label text is otherwise complete.

Symbols in IVD labeling

§ 809.10(g) lets a manufacturer provide required labeling information as a symbol, but only under specific conditions. A symbol accompanied by adjacent explanatory text needs nothing further. A symbol used without adjacent text has to meet one of two tests: it is contained in an FDA-recognized standard and used per that recognition, or it is established in a standards-development-organization standard that the manufacturer determines is likely to be read and understood by the ordinary individual under customary conditions of purchase and use, in compliance with section 502(c) of the act, and used per that standard’s specifications. In either of those two cases, the symbol also has to be explained in a paper or electronic symbols glossary included in the labeling, and the labeling on or within the package has to bear a prominent statement identifying the glossary’s location.

The consequence for getting this wrong is stated directly in the regulation: use of a symbol that doesn’t meet these requirements renders the device misbranded under section 502(c) of the act. Maintain a symbols glossary that lists each symbol used, its source standard, that standard’s title and reference number, and its meaning — and confirm each symbol is either FDA-recognized or meets the SDO-standard conditions before it ships on a label.

Strategic National Stockpile labeling exceptions

§ 809.11 applies only to IVD products that are or will be included in the Strategic National Stockpile. A Strategic National Stockpile official, or an entity that manufactures — including labeling, packing, relabeling, or repackaging — distributes, or stores such a product, may submit a written request for an exception or alternative to listed labeling provisions, with written concurrence from an SNS official. The Center Director may also grant an exception on his or her own initiative, without a written request.

A submitted request has to identify the affected lots, batches, or units and the specific labeling provisions at issue; explain why compliance could adversely affect the safety, effectiveness, or availability of those products; describe the safeguards or conditions that will keep the labeling adequate for safe and effective use under the anticipated circumstances; and include a draft of the proposed labeling. Where the exception applies to a PMA-approved product, the grant has to be identified in the periodic report required under § 814.84 — so the deviation from standard labeling stays visible in postmarket reporting, not just in the request file.

The Part 820 hook: § 809.20

§ 809.20(a) is reserved. § 809.20(b) does the real work: it requires IVD products to be manufactured in accordance with the good manufacturing practice requirements found in part 820, and, if applicable, with § 610.44. This is the clause that pulls the entire quality system regulation onto IVD manufacturing — the same production controls, CAPA, and records requirements that apply to any other device.

Under the current QMSR, § 820.10 (Requirements for a quality management system) incorporates ISO 13485:2016 by reference in full. A quality system built to ISO 13485:2016 and scoped to cover IVD product manufacture satisfies § 809.20(b) — confirm your quality manual’s scope statement says so explicitly, and address § 610.44 separately if the product is also a licensed biological product under the Public Health Service Act.

Joining Part 809 to your quality system

Part 809’s labeling content requirements map onto the same ISO 13485:2016 clause your production and service-provision controls already run through — Clause 7.5.1, control of production and service provision, which the current QMSR reaches through § 820.10. Where package-insert content is generated by your design process rather than assembled at release, ISO 13485:2016 Clause 7.3.4, design and development outputs, also applies: the insert is a design output like any other, subject to the same review and approval before it’s released. The distribution-side restrictions in § 809.30 and § 809.40 — customer eligibility, advertising content, laboratory qualification — don’t map to an ISO 13485 clause at all; they’re Part 809-specific controls on restricted devices, and your procedures should say so rather than force-fitting them under a production-control heading.

Evidence a reviewer will ask for

An FDA investigator or a notified-body reviewer working through your labeling doesn’t start from the regulation text — they start from your controlled documents and ask whether the regulation’s content is reachable from them. The set below covers what each section above depends on:

• A controlled IVD label-content specification and review checklist enumerating every applicable § 809.10(a) element, with release records confirming each is present
• A package-insert template mirroring the § 809.10(b) content order, with revision-dated release records and the applicable reduced-content allowance identified where it applies
• A labeling or design-control procedure that gates the RUO/IUO statement to development stage, with records showing when the statement was removed and on what basis
• A documented general-purpose-reagent classification decision, where § 809.10(d) is applied instead of the full label set
• An ASR customer-eligibility control confirming each sale falls into a § 809.30(b) category or the § 809.30(g) carve-out, plus advertising review records
• A symbols glossary mapping every labeling symbol to its FDA-recognized or SDO-standard basis, with the glossary’s location prominently stated in the labeling itself
• For a Strategic National Stockpile relationship, the § 809.11 request file: SNS-official concurrence, affected units, cited provisions, adverse-effect rationale, safeguards, and draft labeling
• A quality manual scope statement confirming your ISO 13485:2016-based quality system covers IVD product manufacture, satisfying § 809.20(b)

Common findings

The patterns below recur because they sit at the seam between “the label has the right headings” and “the label has the right content under each heading.” Each maps to a specific Part 809 clause.

Additional patterns that recur across small-team labeling reviews:

Expected values without a stated population (§ 809.10(b)).A package insert states a numeric expected-values range but doesn’t identify the population it was established on. § 809.10(b) requires both — a range with no stated population isn’t traceable to the study that produced it.

RUO/IUO statement left on after validation completes (§ 809.10(c)). Labeling continues to carry “For Research Use Only” after the product has been represented as an effective IVD elsewhere, in marketing material or a submission, which is itself inconsistent with the statement’s own condition.

Symbols used without a glossary entry (§ 809.10(g)). A label uses an icon in place of text with no adjacent explanation, and no symbols glossary exists to explain it — or the glossary exists but the label carries no statement telling the user where to find it. Either gap independently renders the device misbranded under section 502(c).

Frequently asked questions

Does a Research Use Only product still need full § 809.10(a)/(b) labeling?

No — while a product is genuinely in the laboratory research phase and not represented as an effective IVD, § 809.10(c) exempts it from the § 809.10(a) and (b) label and package-insert content, provided all labeling instead bears the prominently placed statement “For Research Use Only. Not for use in diagnostic procedures.” A product shipped for product testing before full commercial marketing takes the parallel “For Investigational Use Only” statement. The exemption runs with the statement, not with the product’s general reputation — the moment you represent the product as validated for diagnostic use, or ship it without the statement, the full § 809.10(a)/(b) content applies. Control the transition explicitly: define in a labeling or design-control procedure which development-stage gate removes the RUO/IUO statement, and require that removal only happen once § 809.10(a)/(b) labeling is ready.

Can we sell an analyte specific reagent to any laboratory that asks for one?

No. ASRs are restricted devices under section 520(e) of the FD&C Act, and § 809.30(b) limits sale to three customer categories: IVD manufacturers; CLIA-regulated clinical laboratories qualified to perform high-complexity testing (or laboratories regulated under VHA Directive 1106); and organizations using the reagents for purposes other than providing diagnostic information to patients and practitioners — forensic, academic, research, and other nonclinical laboratories. A laboratory that only performs moderate-complexity testing, for example, does not qualify. § 809.30(g) carves out reagents that otherwise meet the ASR definition but are sold to manufacturers or to those nonclinical-purpose organizations — the labeling, advertising, and laboratory-disclosure requirements in § 809.30(c) through (f) do not apply to that carve-out. Confirm and record customer eligibility before the sale, not after.

Do we need a symbols glossary if our labeling doesn’t use symbols?

No — the glossary requirement in § 809.10(g) is triggered by using a symbol in place of explanatory text, not by labeling in general. A symbol accompanied by adjacent explanatory text needs no glossary entry. A symbol used without adjacent text needs two things: it must be contained in an FDA-recognized standard and used per that recognition, or established in a standards-development-organization standard the manufacturer determines is likely to be read and understood by the ordinary individual under customary conditions of purchase and use; and it must be explained in a symbols glossary included in the labeling, with a prominent statement on or within the package identifying the glossary’s location. Using a symbol that meets neither condition renders the device misbranded under section 502(c) of the act — the consequence attaches to the symbol’s use, not to whether you happen to maintain a glossary.

Is “general-purpose laboratory reagent” something we can self-declare?

It is a classification you apply based on the § 809.10(d) test, not a label you pick for convenience: the reagent’s uses must be generally known by persons trained in its use, with no specific diagnostic claim attached. A hydrochloric acid solution sold for general laboratory work qualifies; the same chemical sold as part of a named diagnostic procedure does not — it becomes a component of an IVD product subject to full § 809.10(a)/(b) labeling instead. Misclassifying a product as general-purpose to avoid the fuller label set is a labeling-content gap, not a labeling-format choice. Document the classification decision and its rationale, not just the resulting label.

We already run a QMSR-based quality system. What does § 809.20 add on top of that?

Section 809.20(b) is the clause that makes the Part 820 quality system requirements apply to IVD manufacturing in the first place, and § 610.44 where it applies. It does not add IVD-specific quality system content beyond that hook. Under the current QMSR, § 820.10 requires a quality management system and incorporates ISO 13485:2016 by reference in full, so a QMS built to ISO 13485:2016 and scoped to cover your IVD manufacturing satisfies § 809.20(b). The practical implication: you do not need a separate “IVD quality system” document alongside your existing QMSR-based system — confirm the scope statement in your quality manual explicitly covers IVD product manufacture, and § 610.44 applicability if the product is also a licensed biological product.

Does the Strategic National Stockpile exception apply to a typical small IVD company?

Rarely, and only where your product is or will be held in the Strategic National Stockpile. § 809.11 lets a Strategic National Stockpile official, or an entity that manufactures, distributes, or stores an in vitro diagnostic product held by the Stockpile, request an exception or alternative to specific listed labeling provisions — for example, where standard labeling could adversely affect the safety, effectiveness, or availability of stockpiled units during an emergency. The written request needs concurrence from an SNS official, must identify the affected lots and the specific labeling provisions at issue, and must include a draft of the proposed labeling; the Center Director may also grant an exception on his or her own initiative. For a PMA-approved product, a granted exception must be reported in the periodic report required under § 814.84. Outside an SNS relationship, this section does not apply to your labeling.

Do OTC drugs-of-abuse test sample collection systems need to disclose false-result rates?

Yes. § 809.10(f) requires labeling in language appropriate for lay users, including a quantitative description of the performance characteristics for each identified drug (sensitivity and specificity) in terms a lay purchaser can understand, and adequate instructions for obtaining and interpreting results — explicitly including the probability of false positive and false negative results and how to contact a trained health professional. § 809.40 adds the operational side: sample testing must run through a laboratory using FDA-approved, cleared, or otherwise recognized screening tests, with recognized capability to perform confirmatory testing and adulteration-integrity checks, and the labeling must provide an adequate system to communicate results back to the lay purchaser. Vague reassurance (“results are highly accurate”) does not satisfy either requirement — the performance characteristics and error rates need to be stated.

Further reading

Regulatory text

21 CFR Part 809 — In Vitro Diagnostic Products for Human Use (current at eCFR.gov). The live source for every section cited in this guide — confirm the current text before finalizing labeling, since amendments don’t always trigger a Federal Register notice you’ll see in the ordinary course of business.

FDA Quality Management System Regulation (QMSR) — 21 CFR Part 820 (current at eCFR.gov). § 820.10 incorporates ISO 13485:2016 by reference — the quality system § 809.20(b) requires your IVD manufacturing to run under.

Internal guides

QMSR Gap Analysis: A Practical Guide — the clause-by-clause process for checking your quality system against ISO 13485 with the QMSR overlay, including where labeling and packaging controls sit inside it.